Analysts Anticipate Cambrex Co. (NYSE:CBM) Will Announce Earnings of $0.47 Per Share

Share on StockTwits

Analysts expect that Cambrex Co. (NYSE:CBM) will report $0.47 earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Cambrex’s earnings. The highest EPS estimate is $0.53 and the lowest is $0.41. Cambrex posted earnings per share of $0.49 during the same quarter last year, which indicates a negative year over year growth rate of 4.1%. The company is scheduled to issue its next earnings results on Thursday, November 14th.

According to Zacks, analysts expect that Cambrex will report full-year earnings of $2.05 per share for the current fiscal year, with EPS estimates ranging from $2.02 to $2.08. For the next financial year, analysts anticipate that the business will report earnings of $1.95 per share. Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Cambrex.

A number of analysts have recently commented on the company. Zacks Investment Research downgraded Cambrex from a “buy” rating to a “hold” rating in a report on Wednesday, July 24th. William Blair downgraded Cambrex from an “outperform” rating to a “market perform” rating and set a $60.00 price objective for the company. in a report on Wednesday, August 7th. ValuEngine downgraded Cambrex from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Finally, Craig Hallum downgraded Cambrex from a “buy” rating to a “hold” rating and set a $60.00 price objective for the company. in a report on Monday, August 12th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $52.00.

CBM stock opened at $59.53 on Friday. The company has a market cap of $2.01 billion, a price-to-earnings ratio of 21.49, a PEG ratio of 4.66 and a beta of 2.19. The company has a quick ratio of 1.77, a current ratio of 2.44 and a debt-to-equity ratio of 0.78. The business has a fifty day simple moving average of $59.62 and a 200-day simple moving average of $47.77. Cambrex has a 52 week low of $33.80 and a 52 week high of $64.11.

Several hedge funds have recently added to or reduced their stakes in CBM. BlackRock Inc. increased its holdings in Cambrex by 2.7% in the 2nd quarter. BlackRock Inc. now owns 5,001,164 shares of the biotechnology company’s stock valued at $234,103,000 after purchasing an additional 132,617 shares in the last quarter. Vanguard Group Inc. increased its holdings in Cambrex by 1.2% in the 2nd quarter. Vanguard Group Inc. now owns 3,504,246 shares of the biotechnology company’s stock valued at $164,034,000 after purchasing an additional 42,200 shares in the last quarter. William Blair Investment Management LLC boosted its position in Cambrex by 2.9% in the 1st quarter. William Blair Investment Management LLC now owns 2,659,481 shares of the biotechnology company’s stock valued at $103,321,000 after buying an additional 75,662 shares during the last quarter. Clearbridge Investments LLC boosted its position in Cambrex by 0.3% in the 1st quarter. Clearbridge Investments LLC now owns 1,337,800 shares of the biotechnology company’s stock valued at $51,974,000 after buying an additional 3,589 shares during the last quarter. Finally, Lazard Asset Management LLC boosted its position in Cambrex by 16.8% in the 1st quarter. Lazard Asset Management LLC now owns 924,844 shares of the biotechnology company’s stock valued at $35,930,000 after buying an additional 133,133 shares during the last quarter.

About Cambrex

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.

Recommended Story: Dollar Cost Averaging

Get a free copy of the Zacks research report on Cambrex (CBM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

AirMedia Group  Upgraded to “Buy” by ValuEngine
AirMedia Group Upgraded to “Buy” by ValuEngine
Iberdrola  Lowered to Sell at ValuEngine
Iberdrola Lowered to Sell at ValuEngine
Telenav  Cut to “Sell” at ValuEngine
Telenav Cut to “Sell” at ValuEngine
NuStar Energy  Downgraded by ValuEngine to Strong Sell
NuStar Energy Downgraded by ValuEngine to Strong Sell
Analysts Expect Constellium NV  to Announce $0.28 EPS
Analysts Expect Constellium NV to Announce $0.28 EPS
PennyMac Mortgage Investment Trust  Stock Holdings Increased by Royal Bank of Canada
PennyMac Mortgage Investment Trust Stock Holdings Increased by Royal Bank of Canada


© 2006-2019 Ticker Report